Negative Impact of Reduced Exocrine Pancreatic Function on Sarcopenia Risk in the Asymptomatic General Population

Why It Matters

The finding identifies subclinical pancreatic insufficiency as a modifiable risk factor for early sarcopenia, highlighting a potential preventive target for younger adults. If confirmed, enzyme supplementation could reduce muscle loss and associated health costs.

Key Takeaways

• Impaired exocrine function raises sarcopenia odds 2.4‑fold in under‑65s
• 9.1% of 5,598 participants had reduced fecal elastase (≤200 µg/g)
• No association found between exocrine insufficiency and sarcopenia in adults 65+
• Long‑term follow‑up showed muscle mass loss but not new sarcopenia cases
• Authors recommend trials of enzyme replacement for asymptomatic low‑elastase individuals

Pulse Analysis

Sarcopenia, the progressive loss of muscle mass and strength, is a major driver of disability, falls, and health‑care expenditures worldwide. While aging remains the most recognized cause, emerging research points to metabolic and gastrointestinal factors that can accelerate muscle deterioration. One such factor is exocrine pancreatic insufficiency (EPI), a condition where the pancreas fails to secrete enough digestive enzymes, leading to subtle malabsorption of nutrients essential for muscle maintenance. Population‑based estimates suggest that up to 20% of adults harbor subclinical EPI, yet its broader health implications have been largely unexplored until now.

The recent Frontiers in Nutrition study leveraged two large German cohorts to examine this gap. Among 5,598 participants without known pancreatic disease, 9.1% exhibited low fecal elastase, the standard non‑invasive marker of exocrine function. Cross‑sectional analysis revealed that younger individuals (<65) with impaired pancreatic function faced more than double the odds of sarcopenia compared with peers, even after adjusting for BMI, smoking, diabetes, and physical inactivity. In contrast, the association vanished in the older subgroup, suggesting that age‑related sarcopenia may be driven by a different constellation of risk factors. Longitudinally, low elastase predicted a measurable decline in skeletal muscle mass over five years, although it did not translate into a higher incidence of full‑blown sarcopenia within the study period.

These findings open a new preventive avenue: targeting subclinical EPI before overt muscle loss occurs. Pancreatic enzyme replacement therapy (PERT) is already standard care for patients with chronic pancreatitis or pancreatic cancer, where it improves nutritional status and quality of life. If randomized trials confirm that PERT can halt or reverse early muscle decline in otherwise healthy adults, clinicians could incorporate fecal elastase screening into routine geriatric or primary‑care assessments. Such a shift would not only expand the therapeutic toolkit for sarcopenia but also potentially curb downstream costs associated with fractures, hospitalizations, and long‑term care. Future research should prioritize diverse populations, longer follow‑up, and mechanistic studies linking enzyme deficiency to micronutrient gaps and gut‑microbiome alterations that may underlie muscle catabolism.